STOCK TITAN

Coherus Oncology (CHRS) SEC Filings

CHRS NASDAQ

Coherus Oncology, Inc. filings document an oncology operating company with Nasdaq-listed common stock and disclosures tied to LOQTORZI commercialization, antibody immunotherapy development and capital formation. Form 8-K reports cover operating results and business updates, preliminary financial information, clinical supply arrangements involving tagmokitug, and equity transactions under shelf registration, at-the-market and underwritten public offering structures.

Proxy and other filings describe board elections, executive compensation, equity awards, shareholder voting matters, registered securities, governance practices, risk disclosures and the company's capital structure, including common stock issuance and offering-related agreements.

Rhea-AI Summary

Coherus Oncology, Inc. (CHRS) reported third-quarter 2026 net revenue of $14.274 million, up from $11.571 million a year earlier, with LOQTORZI net revenue rising to $14.009 million from $11.169 million. Net loss widened from $35.531 million to $39.334 million, while loss from continuing operations narrowed from $44.517 million to $38.875 million.

For the nine months ended September 30, 2026, net revenue was $40.891 million, compared with $29.424 million, and net cash used in operating activities was $153.995 million, compared with $118.797 million. Cash, cash equivalents and marketable securities totaled $83.6 million as of September 30, 2026. The company drew the full $55.0 million Term A Loan on August 14, 2026; it matures on August 14, 2031.

Management said existing cash resources may be exhausted within one year after the financial statements are issued unless the company generates additional operating cash flows, raises capital, reduces costs or takes other strategic actions. Management concluded that substantial doubt about the company’s ability to continue as a going concern had not been alleviated.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.61%
Tags
quarterly report
-
Rhea-AI Summary

Coherus Oncology, Inc. (CHRS) reported third-quarter 2026 results and a strategic plan to focus tagmokitug/toripalimab development on esophageal cancer. Continuing-operations revenue was $14.3 million, versus $11.6 million a year earlier; continuing-operations net loss was $38.9 million, versus $44.5 million.

The company will continue first-line ESCC and second-line ESCC and EAC studies, deprioritize other cohorts, and seek FDA alignment on an expedited path initially focused on second-line esophageal cancer. For second-line ESCC/EAC cohorts, median progression-free survival was 5.5 months; in the 700 mg subgroup, clinical benefit rate was 55.6% and confirmed overall response rate was 33.3%. Data were as of October 14, 2026. The plan includes an approximately 30% workforce reduction.

Coherus said the changes will lower quarterly core cash burn by $6 million to $7 million over the next two quarters, with LOQTORZI revenue needed to cover core burn reduced to $25 million to $30 million from previously guided $30 million to $35 million. Cash, cash equivalents and marketable securities totaled $83.6 million as of September 30, 2026, versus $172.1 million as of December 31, 2025; balances included TSA-related collections to be applied to associated TSA payables and accrued liabilities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.61%
Tags
current report
-
Rhea-AI Summary

Coherus Oncology, Inc. (CHRS) reported interim clinical results for tagmokitug, an investigational cytolytic CCR8 antibody, in combination with toripalimab, with or without chemotherapy. In first-line ESCC, tagmokitug 700 mg plus toripalimab, 5-fluorouracil and cisplatin had a confirmed overall response rate (cORR) of 75% (6/8) among efficacy-evaluable patients as of October 14, 2026; cORR was 100% in PD-L1-positive patients. After the cutoff, the reported cORR was 89% (8/9).

In the second-line ESCC 700 mg arm, clinical benefit rate was 33.3% (2/6), cORR was 16.7% (1/6), and median progression-free survival was 5.5 months. Among 120 patients treated with tagmokitug plus toripalimab, immune-related adverse events occurred in 40%, including Grade 3-5 events in 20%; no Grade 5 treatment-related adverse events were reported. In 33 monotherapy patients, no dose-limiting toxicities were observed through 1,200 mg every three weeks. Coherus plans to expand both ESCC cohorts; tagmokitug remains investigational, and its safety and efficacy have not been established.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.55%
Tags
current report
Rhea-AI Summary

Coherus Oncology, Inc. (CHRS) entered into a sales agreement with Leerink Partners LLC allowing "at the market" issuances of its common stock with an aggregate offering price of up to $50.0 million. Leerink may act as sales agent or principal under a Form S-3 shelf registration declared effective on December 8, 2025.

Coherus will pay Leerink a commission of up to 3.0% of gross proceeds from each sale, and either party may terminate the agreement on ten days’ notice. Coherus intends to use any net cash proceeds for general corporate purposes, including working capital.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.26%
Tags
current report
-
Rhea-AI Summary

Coherus Oncology, Inc. (CHRS) filed a prospectus supplement establishing an at-the-market equity program to issue and sell up to $50,000,000 of common stock under its existing $150.0 million shelf registration. Sales will be made from time to time through Leerink Partners LLC as sales agent on the Nasdaq Global Market.

Leerink Partners may conduct sales deemed to be an “at the market offering” under Rule 415, earning up to 3.0% of gross proceeds plus up to $100,000 of reimbursed legal expenses. Coherus expects to use any net proceeds for general corporate purposes, including working capital, R&D, commercial activities and capital expenditures, pending investment in short-term investment-grade securities.

The company highlights risks including potential dilution to investors, fluctuating share sale prices under the ATM, and significant indebtedness under a Loan and Security Agreement with Innovatus Life Sciences Lending Fund I, LP, which imposes financial and operational covenants and could adversely affect liquidity if breached.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.26%
Tags
prospectus
-
Rhea-AI Summary

Coherus Oncology, Inc. (CHRS) is formally ending its existing at-the-market equity offering program under a prior sales agreement. Under that agreement, the company could offer and sell common stock with an aggregate offering price of up to $92,500,000, and had previously registered the offer and sale of up to $64,880,054 of common stock under a January 2026 prospectus. On August 17, 2026, Coherus notified the agent that it was terminating the sales agreement because it is entering into a new sales agreement with a different agent. This supplement terminates the continuous offering under the January 2026 prospectus and the related sales agreement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.26%
Tags
prospectus
Rhea-AI Summary

Coherus Oncology, Inc. announced a special dividend of contingent value rights (CVRs) tied to its remaining biosimilar business. Stockholders of record of Coherus common stock at 5:00 p.m. Eastern Time on September 30, 2026 (the Record Date) will receive one CVR for each share held.

The CVRs will be distributed on October 7, 2026 and will entitle holders to their pro rata share of any net cash proceeds that Coherus actually receives from selling, licensing, or otherwise monetizing specified “Legacy BioSim Assets,” including patents, an existing royalty stream, cell lines and related materials, during the CVR term. The CVR term runs from October 7, 2026 through October 7, 2028; if no qualifying net proceeds are received in that period, the CVRs will expire without payment.

The CVRs are non-transferable except in limited cases, will not be certificated, carry no voting or dividend rights, and will not be listed or traded. Payments, if any, are subject to deductions for taxes and specified expenses and to restrictions in Coherus’ August 12, 2026 Loan and Security Agreement with Innovatus Life Sciences Lending Fund I, L.P.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.52%
Tags
current report
-
Rhea-AI Summary

Coherus Oncology, Inc. entered into a new senior secured term loan facility of $55,000,000 with Innovatus Life Sciences Lending Fund I, LP and other lenders, maturing in August 2031. On August 14, 2026, Coherus drew the full Tranche A amount and used a portion to repay and terminate its prior senior secured term loan, which had been scheduled to mature in May 2029 and carried interest at 8.0% plus three‑month SOFR. Remaining proceeds are designated for working capital and general business requirements.

The new Term Loans bear a floating rate of 4.15% plus the greater of the Prime Rate or 6.75%, with an initial 36‑month interest‑only period, extendable to 48 months upon achieving specified revenue and market capitalization milestones. Coherus also has the option to draw additional tranches of $25,000,000 and $20,000,000 under certain conditions. The loans are secured by liens on substantially all borrower assets, include a minimum unrestricted cash covenant, facility and prepayment fees, and a 4.00% final fee that can increase to 10.00% if the company begins an insolvency proceeding and receives specified debtor‑in‑possession financing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.52%
Tags
current report
-
Rhea-AI Summary

Coherus Oncology, Inc. reported Q2 2026 net revenue from continuing operations of $14.3 million, up from $10.3 million a year earlier, driven mainly by LOQTORZI sales of $13.6 million. Gross margin from continuing operations was 70%.

Research and development expense fell to $21.4 million and selling, general and administrative expense to $21.0 million, reflecting lower headcount and the exit from biosimilars. The company recorded a Q2 2026 net loss from continuing operations of $33.3 million and total net loss of $20.6 million, partly offset by $12.7 million of income from discontinued operations tied to prior biosimilar divestitures.

At June 30, 2026, Coherus held $105.3 million in cash, cash equivalents and marketable securities, with a $37.2 million 2029 term loan and a $14.8 million revenue participation liability outstanding. Management believes existing liquidity funds operations for at least 12 months but indicates additional capital will be needed to complete development and commercialization plans.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.76%
Tags
quarterly report
Rhea-AI Summary

Coherus Oncology reported second quarter 2026 net revenue from continuing operations of $14.3 million, up from $10.3 million a year earlier, driven mainly by LOQTORZI, which generated $13.6 million in net revenue, 15% above the prior quarter. Cost of goods sold was $4.2 million, while R&D and SG&A expenses declined versus 2025 as the company reduced headcount and completed its exit from the biosimilar business.

The company recorded a GAAP net loss from continuing operations of $33.3 million, or $0.22 per share, compared with a $44.9 million loss, or $0.39 per share, in 2025; non-GAAP net loss narrowed to $30.1 million. Cash, cash equivalents and marketable securities totaled $105.3 million at June 30, 2026, down from $172.1 million at year-end 2025. Coherus highlighted clinical progress for tagmokitug and casdozokitug and anticipates publicly disclosing data sets with sufficient maturity in early October 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.76%
Tags
current report

FAQ

How many Coherus Oncology (CHRS) SEC filings are available on StockTitan?

StockTitan tracks 56 SEC filings for Coherus Oncology (CHRS), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Coherus Oncology (CHRS)?

The most recent SEC filing for Coherus Oncology (CHRS) was filed on November 9, 2026.